Jiancheng Yang

Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation

Jiancheng Yang, Ming Yang, Yuhong Zeng

Denosumab is a first-line therapy for osteoporosis, yet the rebound increase in bone turnover markers, rapid bone loss, and elevated fracture risk following its discontinuation have become major challenges in clinical management. This review systematically summarizes the potentia…Read more